uniQure Q2 2026: FDA Greenlights AMT-130 BLA Path, Cash Runway Extended to 2030
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure's Q2 2026 filing reveals FDA alignment on an accelerated approval path for its Huntington's disease gene therapy AMT-130, with a BLA submission planned for Q3 2026. Positive early data for AMT-260 and AMT-191 were also reported, and the company ended the quarter with $810.3 million in cash, extending its runway into 2030.
Key Events · Earnings and Guidance · QURE
-
FDA Aligns on AMT-130 BLA Path
In June 2026, the FDA agreed that a BLA submission for AMT-130 under accelerated approval is reasonable, with submission expected in Q3 2026. Prior to filing, the agency seeks alignment on a confirmatory study design.
-
Q2 2026 Financial Results
Revenue of $5.8 million was offset by a net loss of $81.1 million. As of June 30, 2026, cash, cash equivalents, and investment securities totaled $810.3 million, providing runway into 2030.
-
AMT-260 Phase I/IIa Preliminary Data
In the low-dose cohort, three of six patients achieved a 79% to 100% reduction in disabling seizures during months four through six of follow-up. No serious adverse events related to AMT-260 were reported.
-
AMT-191 Fabry Disease Program Update
Dose-dependent α-Gal A activity was observed across 11 patients, all of whom have been withdrawn from enzyme replacement therapy. Dosing in the mid- and high-dose cohorts has been paused pending evaluation of asymptomatic liver enzyme elevations.
Analysis · QURE · Life Sciences
The Q2 2026 report from uniQure packs several positive catalysts. Most notably, the FDA has agreed that a BLA submission for AMT-130 under accelerated approval is reasonable, with filing expected in Q3 2026 — a major de-risking event following earlier regulatory setbacks. Encouraging early data also emerged for AMT-260 in epilepsy, alongside updated AMT-191 Fabry disease results. Financially, the company closed the quarter with $810.3 million in cash and investments, extending its runway into 2030, bolstered by a $242.7 million follow-on offering in June. Together, the regulatory progress, clinical data, and strengthened balance sheet significantly enhance the investment thesis.
At the time of this filing, QURE was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.